How does ONYX's PE Ratio compare to its peers?

ONYX is good value based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (59.3x).

How does ONYX's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

ONYX is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the Indian Pharmaceuticals industry average (34.8x).

What is ONYX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ONYX's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of ONYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ONYX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

ONYX Stock Overview

Develops, manufactures, and distributes generic pharmaceutical products in India and internationally. More details

ONYX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	3/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings grew by 64.4% over the past year

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Does not have a meaningful market cap (₹977M)

My Notes

Capture your thoughts, links and company narrative

Onyx Biotec Limited Competitors

Biofil Chemicals and Pharmaceuticals

BSE:524396

₹991.6m

Vasundhara Rasayans

BSE:538634

₹946.6m

Makers Laboratories

BSE:506919

₹998.9m

JFL Life Sciences

NSEI:JFLLIFE

₹1.1b

Price History & Performance

Summary of share price highs, lows and changes for Onyx Biotec
Historical stock prices
Current Share Price	₹64.65
52 Week High	₹62.50
52 Week Low	₹51.00
Beta	0
1 Month Change	9.67%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	13.92%

Recent updates

Shareholder Returns

	ONYX	IN Pharmaceuticals	IN Market
7D	18.1%	0.2%	-2.5%
1Y	n/a	38.1%	17.9%

Return vs Industry: Insufficient data to determine how ONYX performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ONYX performed against the Indian Market.

Price Volatility

Is ONYX's price volatile compared to industry and market?
ONYX volatility
ONYX Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.1%

Stable Share Price: ONYX's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine ONYX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Harsh Mahajan	www.onyxbiotec.com

Onyx Biotec Limited develops, manufactures, and distributes generic pharmaceutical products in India and internationally. The company offers sterile water for injections; and acts as a pharmaceutical contract manufacturer for a range of dry powder injections and dry powder syrups cephalosporins. It also exports its products.

Onyx Biotec Limited Fundamentals Summary

How do Onyx Biotec's earnings and revenue compare to its market cap?
ONYX fundamental statistics
Market cap	₹977.31m
Earnings (TTM)	₹30.32m
Revenue (TTM)	₹537.49m

38.7x

P/E Ratio

2.2x

P/S Ratio

Is ONYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONYX income statement (TTM)
Revenue	₹537.49m
Cost of Revenue	₹367.28m
Gross Profit	₹170.21m
Other Expenses	₹139.90m
Earnings	₹30.32m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.67
Gross Margin	31.67%
Net Profit Margin	5.64%
Debt/Equity Ratio	123.7%

How did ONYX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 13:12
End of Day Share Price	2024/12/26 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onyx Biotec Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Onyx Biotec NSEI:ONYX Stock Report